Sign in Subscribe

Caroline Thorn, Curator

New PharmGKB pathway for Cannabidiol Pharmacokinetics

PharmGKB released a new pharmacokinetics pathway for Cannabidiol, a phytocannabionoid found in the Cannabis sativa plant approved to treat two rare forms of epilepsy. The pathway was produced by graduate student Kris Oreschak from the University of Colorado Denver Anschutz Medical Campus with guidance from scientific curator Dr Caroline F.

Curators' Favorite Papers

An article in Pharmacogenomics Journal puts the spotlight on the need to continue look for candidate genes and variants in many populations even when it seems as though current candidates explain a large amount of variability. [PMID: 30100615] identifies new candidate genes and variants that are important when the most

PharmGKB Clozapine PK Pathway appears on the cover of Pharmacogenetics and Genomics

The Clozapine Pharmacokinetics Pathway is featured on the cover of September 2018 volume 28 issue 9 of Pharmacogenetics and Genomics. This pathway shows the candidate genes involved in the metabolism of the antipsychotic drug clozapine and was developed by curator Dr Caroline F. Thorn with Professor Daniel Mueller of the

Promote the study of Pharmacogenomics in the All of Us cohort

The NIH is collecting suggestions for what to study in a new large cohort of one million or more people living in the United States. The All of Us research program is part of the Precision Medicine Initiative and will recruit volunteers across the USA to share their data with

10 New Pharmacokinetics Pathways on PharmGKB

PharmGKB releases ten new PK pathways on the website: Antidepressants: Amitriptyline and Nortriptyline, Fluvoxamine, and BupropionAntipsychotics: Clozapine, Haloperidol and Olanzapine Antiepileptic: ClobazamNSAIs: NaproxenAnti-cancer drug: DasatinibAnti-hypertensive drug: Verapamil If you are interested in collaborating to develop these for publication as a PharmGKB summary in Pharmacogenetics and Genomics journal please email feedback@

Thiopurine Pathway updated with new candidate genes

Thiopurines and TPMT have long been a cornerstone of PGx research. As such the Thiopurine Pathway was one of the earliest pathways in PharmGKB to be published in Pharmacogenetics and Genomics [PMID:19952870]. In collaboration with Jun Yang, Takaya Moriyama and Rina Nishii from St Judes, we have substantially updated

Introducing the new PharmGKB Cancer PGx Portal

PharmGKB has collected a number of resources for Cancer PGx into one easy location. There are tables with direct links to genes important for cancer drug response both for PD and PK, to cancer drug pathways, particular cancers that have PGx data, types of toxicities common to cancer drugs, and

DPYD testing saves money as well as prevents fluoropyrimidine toxicity

A recent article [PMID: 26573078] and editorial [PMID: 26644533] in The Journal of Clinical Oncology looked at prospective testing for DPYD *2A and prevention of grade 3 or higher toxicity. The study examined a large number of patients (n=2,038) and identified 22 carriers of DPYD *2A who then

Cisplatin FDA label changes

In 2013 we blogged about the controversy with the FDA labeling for cisplatin and its warning for TPMT variants and increased risk of ototoxicity in children. The 2012 label stated: “Certain genetic variants in the thiopurine S-methyltransferase gene (e.g., TPMT*3B and TPMT*3C) are associated with an increased

Combining large PGx datasets from cancer cell lines

Testing cancer cell lines in vitro for drug sensitivity is a cornerstone of preclinical drug development. Large publically available datasets can be found at The Genomics of Drug Sensitivity in Cancer Project(GDSE) and The Cancer Cell Line Encyclopedia (CCLE). Studies attempting to combine large public datasets and analyzing for